Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: S-Adenosylmethionine and Urokinase-Type Plasminogen Activator

Research Papers that Mention the Interaction

The mechanism may be that SAM can reverse the hypomethylation of c-myc and uPA genes , reduce their expression, and then inhibit tumor growth.
The protein and mRNA expressions of c-myc and uPA were remarkably reduced (all P < 0.01), and the hypomethylation of c-myc and uPA genes were reversed after SAM treatment.
Chinese journal of cancer  •  2010  |  View Paper
Immunohistochemical analysis of tumors showed the ability of SAM and MBD2-AS to significantly decrease tumoral uPA and MMP-2 expression along with levels of angiogenesis and survival pathway signaling molecules.
Cancer research  •  2006  |  View Paper
Treatment of MDA-231 cells with AdoMet , but not its unmethylated analogue S-adenosylhomocysteine, significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and metastasis in vivo.
Journal of Biological Chemistry  •  2004  |  View Paper
SAM can reverse the methylation of c-myc and uPA in these two cell lines and reduce their expression.
The methylation of c-myc and uPA genes in two cell lines were reversed after SAM treatment.
Zhonghua yi xue za zhi  •  2010  |  View Paper
Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
Cancer research  •  2007  |  View Paper